Hainan Huluwa Pharmaceutical Group Co (SHSE:605199) Cyclically Adjusted FCF per Share: ¥-0.32 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:605199 Hainan Huluwa Pharmaceutical Group Co Ltd SHSE:605199
52 GF Score
Price ¥6.01
GF Value ¥5.81
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Hainan Huluwa Pharmaceutical Group Co Cyclically Adjusted FCF per Share?

Hainan Huluwa Pharmaceutical Group Co SHSE:605199 +3.80% 52 Cyclically Adjusted FCF per Share is ¥-0.32 as of Mar. 2026. GuruFocus rates SHSE:605199 with a GF Score™ of 52/100 and a GF Value™ of ¥5.81 (Fairly Valued). The stock has 9 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Hainan Huluwa Pharmaceutical Group Co's adjusted free cash flow per share data for the fiscal year that ended in Dec. 2025 was ¥0.133. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ¥-0.32 for the trailing ten years ended in Dec. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-08-06), Hainan Huluwa Pharmaceutical Group Co's current stock price is ¥ 6.01. Hainan Huluwa Pharmaceutical Group Co's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec. 2025 was ¥-0.32. Hainan Huluwa Pharmaceutical Group Co's Cyclically Adjusted Price-to-FCF of today is .


Hainan Huluwa Pharmaceutical Group Co  (SHSE:605199) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Hainan Huluwa Pharmaceutical Group Co Cyclically Adjusted FCF per Share Related Terms


Hainan Huluwa Pharmaceutical Group Co Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Hainan Huluwa Pharmaceutical Group Co's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hainan Huluwa Pharmaceutical Group Co Cyclically Adjusted FCF per Share Chart

Hainan Huluwa Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.32

Hainan Huluwa Pharmaceutical Group Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.32 0.00

SHSE:605199 vs ZTS: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hainan Huluwa Pharmaceutical Group Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hainan Huluwa Pharmaceutical Group Co Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hainan Huluwa Pharmaceutical Group Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Hainan Huluwa Pharmaceutical Group Co's Cyclically Adjusted Price-to-FCF falls into.


SHSE:605199
52GF Score
Hainan Huluwa Pharmaceutical Group Co Ltd SHSE:605199
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hainan Huluwa Pharmaceutical Group Co Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Hainan Huluwa Pharmaceutical Group Co's adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=0.133/115.8323*115.8323
=0.133

Current CPI (Dec. 2025) = 115.8323.

Hainan Huluwa Pharmaceutical Group Co Annual Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201612 0.000 102.600 0.000
201712 -0.397 104.500 -0.440
201812 -0.126 106.500 -0.137
201912 0.236 111.200 0.246
202012 -0.148 111.500 -0.154
202112 -0.088 113.108 -0.090
202212 -0.376 115.116 -0.378
202312 -1.274 114.781 -1.286
202412 -0.768 114.893 -0.774
202512 0.133 115.832 0.133

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of ¥-0.32 mean?
Hainan Huluwa Pharmaceutical Group Co (SHSE:605199) has a Cyclically Adjusted FCF per Share of ¥-0.32 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Hainan Huluwa Pharmaceutical Group Co and its competitors.
Is Hainan Huluwa Pharmaceutical Group Co's Cyclically Adjusted FCF per Share too high?
Hainan Huluwa Pharmaceutical Group Co's current Cyclically Adjusted FCF per Share is ¥-0.32. Overall, Hainan Huluwa Pharmaceutical Group Co has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hainan Huluwa Pharmaceutical Group Co's Cyclically Adjusted FCF per Share compare to ZTS?
Hainan Huluwa Pharmaceutical Group Co's Cyclically Adjusted FCF per Share of ¥-0.32 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Hainan Huluwa Pharmaceutical Group Co and its competitors. Hainan Huluwa Pharmaceutical Group Co's current Cyclically Adjusted FCF per Share is ¥-0.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hainan Huluwa Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Hainan Huluwa Pharmaceutical Group Co (SHSE:605199) is currently considered Fairly Valued. The stock's GF Value™ is ¥5.81, compared to a current price of ¥6.01 — trading 3.4% above its estimated fair value. The current Cyclically Adjusted FCF per Share is ¥-0.32. Hainan Huluwa Pharmaceutical Group Co's overall GF Score™ is 52/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Hainan Huluwa Pharmaceutical Group Co (SHSE:605199), the current Cyclically Adjusted FCF per Share is ¥-0.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hainan Huluwa Pharmaceutical Group Co (SHSE:605199) Overvalued in 2026?

Based on GuruFocus' analysis, Hainan Huluwa Pharmaceutical Group Co stock appears to be overvalued. The current stock price of ¥6.01 is trading 3.4% above its estimated GF Value™ of ¥5.81. GuruFocus considers Hainan Huluwa Pharmaceutical Group Co to be Fairly Valued.

Key valuation signals for SHSE:605199:

  • Cyclically Adjusted FCF per Share: ¥-0.32
  • GF Value™: ¥5.81 vs. price of ¥6.01 (3.4% above fair value)
  • GF Score™: 52/100 with 9 warning signs

No single metric tells the full story. See the SHSE:605199 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hainan Huluwa Pharmaceutical Group Co Business Description

Address No. 8, Yaogu 4th Road, Phase II, Yaogu Industrial Park, Haikou National High-tech Zone, Hainan Province, Haikou, CHN, 570300
Hainan Huluwa Pharmaceutical Group Co Ltd is engaged in production and sales of Chinese patent medicines and chemical drugs. The company produces medicines for children's respiratory and digestive systems. Its products include star products, calabash, gourd dad, and gourd mom.
52GF Score

Get the complete analysis for SHSE:605199

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥6.01
Price
¥5.81
GF Value